Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 6

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Effects of sleep disturbances and circadian rhythms modifications on cognition in breast cancer women before and after adjuvant chemotherapy: the ICANSLEEP-1 protocol

Elia, Clara, de Girolamo, Laura, Clarisse, Bénédicte, Galin, Melvin, Rehel, Stéphane, Clochon, Patrice, Doidy, Franck, Segobin, Shailendra, Viader, Fausto, Naveau, Mikaël, Delcroix, Nicolas, Segura-Djezzar, Carine, Grellard, Jean-Michel, Lequesne, Justine, Etard, Olivier, Martin, Tristan, Quarck, Gaëlle, Eustache, Francis, Joly, Florence, Giffard, Bénédicte, Perrier, Joy·2023·BMC Cancer
DOI 10.1186/s12885-023-11664-x
Open this paper in CoChat — free account

Abstract

Background: Many patients treated for breast cancer (BC) complain about cognitive difficulties affecting their daily lives. Recently, sleep disturbances and circadian rhythm disruptions have been brought to the fore as potential contributors to cognitive difficulties in patients with BC. Yet, studies on these factors as well as their neural correlates are scarce. The purpose of the ICANSLEEP-1 (Impact of SLEEP disturbances in CANcer) study is to characterize sleep using polysomnography and its relationship with the evolution of cognitive functioning at both the behavioral and the neuroanatomical levels across treatment in BC patients treated or not with adjuvant chemotherapy. Methods: ICANSLEEP-1 is a longitudinal study including BC patients treated with adjuvant chemotherapy (n = 25) or not treated with adjuvant chemotherapy (n = 25) and healthy controls with no history of BC (n = 25) matched for age (45–65 years old) and education level. The evaluations will take place within 6 weeks after inclusion, before the initiation of chemotherapy (for BC patients who are candidates for chemotherapy) or before the first fraction of radiotherapy (for BC patients with no indication for chemotherapy) and 6 months later (corresponding to 2 weeks after the end of chemotherapy). Episodic memory, executive functions, psychological factors, and quality of life will be assessed with validated neuropsychological tests and self-questionnaires. Sleep quantity and quality will be assessed with polysomnography and circadian rhythms with both actigraphy and saliva cortisol. Grey and white matter volumes, as well as white matter microstructural integrity, will be compared across time between patients and controls and will serve to further investigate the relationship between sleep disturbances and cognitive decline. Discussion: Our results will help patients and clinicians to better understand sleep disturbances in BC and their relationship with cognitive functioning across treatment. This will aid the identification of more appropriate sleep therapeutic approaches adapted to BC patients. Improving sleep in BC would eventually help limit cognitive deficits and thus improve quality of life during and after treatments. Trial registration: NCT05414357, registered June 10, 2022. Protocol version: Version 1.2 dated March 23, 2022.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12885-023-11664-x

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 83

  1. Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, et al. Cancer statistics for the year 2020: An overview. Int J Cancer. 15 août 2021;149(4):778–89. · DOI
  2. Boykoff N, Moieni M, Subramanian SK. Confronting chemobrain: an in-depth look at survivors’ reports of impact on work, social networks, and health care response. J Cancer Surviv. 2009;3(4):223–32. · DOI
  3. Lange M, Licaj I, Clarisse B, Humbert X, Grellard J, Tron L et al. Cognitive complaints in cancer survivors and expectations for support: Results from a web–based survey. Cancer Med. 18 mars 2019;8(5):2654–63. · DOI
  4. Giffard B, Lange M, Léger I. Les troubles cognitifs légers liés Au cancer: comment Et à quelles fins les évaluer en consultation neuropsychologique ? Rev Neuropsychol. 2015;7(2):127.
  5. Wefel JS, Kesler SR, Noll KR, Schagen SB. Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults: Cancer-related cognitive impairment. CA Cancer J Clin mars. 2015;65(2):123–38. · DOI
  6. Ahles TA, Saykin AJ, McDonald BC, Furstenberg CT, Cole BF, Hanscom BS, et al. Cognitive function in Breast cancer patients prior to adjuvant treatment. Breast Cancer Res Treat Juill. 2008;110(1):143–52. · DOI
  7. Wefel JS, Lenzi R, Theriault R, Buzdar AU, Cruickshank S, Meyers CA. Chemobrain’ in breast carcinoma? Cancer. 2004;101(3):466–75. · DOI
  8. Janelsins MC, Kesler SR, Ahles TA, Morrow GR. Prevalence, mechanisms, and management of cancer-related cognitive impairment. Int Rev Psychiatry févr. 2014;26(1):102–13. · DOI
  9. Hurria A, Goldfarb S, Rosen C, Holland J, Zuckerman E, Lachs MS, et al. Effect of adjuvant Breast cancer chemotherapy on cognitive function from the older patient’s perspective. Breast Cancer Res Treat août. 2006;98(3):343–8. · DOI
  10. Lange M, Heutte N, Noal S, Rigal O, Kurtz J, Lévy C, et al. Cognitive changes after adjuvant treatment in older adults with early-stage Breast Cancer. The Oncologist janv. 2019;24(1):62–8. · DOI
  11. Koppelmans V, Breteler MMB, Boogerd W, Seynaeve C, Gundy C, Schagen SB. Neuropsychological performance in survivors of Breast Cancer more than 20 years after adjuvant chemotherapy. J Clin Oncol 1 avr. 2012;30(10):1080–6. · DOI
  12. Amidi A, Wu LM. Circadian disruption and cancer- and treatment-related symptoms. Front Oncol 28 oct. 2022;12:1009064. · DOI · Paper page
  13. Duivon M, Giffard B, Desgranges B, Perrier J. Are Sleep complaints related to cognitive functioning in non-central nervous System Cancer? A systematic review. Neuropsychol Rev [Internet] 5 août 2021 [cité 30 nov 2021]; Disponible sur: https://link.springer.com/https://doi.org/10.1007/s11065-021-09521-4. · DOI
  14. Perrier J, Duivon M, Rauchs G, Giffard B. Le Sommeil dans les cancers non cérébraux: revue de la littérature, mécanismes potentiels et perspectives pour mieux comprendre les troubles cognitifs associés. Médecine Sommeil juin. 2021;18(2):90–103. · DOI
  15. Ancoli-Israel S, Liu L, Natarajan L, Rissling M, Neikrug AB, Youngstedt SD, Mills PJ, Sadler GR, Dimsdale JE, Parker BA, Palmer BW. Reductions in sleep quality and circadian activity rhythmicity predict longitudinal changes in objective and subjective cognitive functioning in women treated for Breast cancer. Supportive care in cancer: Official Journal of the Multinational Association of Supportive Care in Cancer. 2022;30(4):3187–200. https://doi.org/10.1007/s00520-021-06743-3. · DOI · Paper page
  16. Diekelmann S, Born J. The memory function of sleep. Nat Rev Neurosci févr. 2010;11(2):114–26. · DOI · Paper page
  17. Wilckens KA, Woo SG, Kirk AR, Erickson KI, Wheeler ME. The role of sleep continuity and total sleep time in executive function across the adult lifespan. Psychol Aging Sept. 2014;29(3):658–65. · DOI
  18. Costa AR, Fontes F, Pereira S, Gonçalves M, Azevedo A, Lunet N. Impact of Breast cancer treatments on sleep disturbances – A systematic review. The Breast déc. 2014;23(6):697–709. · DOI
  19. Savard J, Ivers H, Villa J, Caplette-Gingras A, Morin CM. Natural course of Insomnia Comorbid with Cancer: an 18-Month Longitudinal Study. J Clin Oncol 10 sept. 2011;29(26):3580–6. · DOI
  20. Deboer T. Sleep homeostasis and the circadian clock: do the circadian pacemaker and the sleep homeostat influence each other’s functioning? Neurobiol Sleep Circadian Rhythms 1 mars. 2018;5:68–77. · DOI
  21. Montaruli A, Castelli L, Mulè A, Scurati R, Esposito F, Galasso L, et al. Biological Rhythm and Chronotype: New perspectives in Health. Biomolecules Avr. 2021;11(4):487. · DOI
  22. Mogavero MP, DelRosso LM, Fanfulla F, Bruni O, Ferri R. Sleep disorders and cancer: state of the art and future perspectives. Sleep Med Rev 1 avr. 2021;56:101409. · DOI
  23. Samuelsson LB, Bovbjerg DH, Roecklein KA, Hall MH. Sleep and circadian disruption and incident Breast cancer risk: an evidence-based and theoretical review. Neurosci Biobehav Rev janv. 2018;84:35–48. · DOI
  24. Abercrombie HC, Giese-Davis J, Sephton S, Epel ES, Turner-Cobb JM, Spiegel D. Flattened cortisol rhythms in metastatic Breast cancer patients. Psychoneuroendocrinology sept. 2004;29(8):1082–92. · DOI
  25. Hsiao FH, Jow GM, Kuo WH, Wang MY, Chang KJ, Lai YM, et al. A longitudinal study of diurnal cortisol patterns and associated factors in Breast cancer patients from the transition stage of the end of active cancer treatment to post-treatment survivorship. The Breast déc. 2017;36:96–101. · DOI
  26. Liu L, Rissling M, Neikrug A, Fiorentino L, Natarajan L, Faierman M, et al. Fatigue and circadian activity rhythms in Breast Cancer patients before and after chemotherapy: a controlled study. Fatigue Abingdon Eng Print. 2013;1(1–2):12–26.
  27. Roveda E, Bruno E, Galasso L, Mulè A, Castelli L, Villarini A, et al. Rest-activity circadian rhythm in Breast cancer survivors at 5 years after the primary diagnosis. Chronobiol Int 3 août. 2019;36(8):1156–65. · DOI
  28. Savard J, Liu L, Natarajan L, Rissling MB, Neikrug AB, He F, et al. Breast Cancer patients have progressively impaired sleep-wake activity rhythms during chemotherapy. Sleep 1 sept. 2009;32(9):1155–60. · DOI
  29. Beck SL, Berger AM, Barsevick AM, Wong B, Stewart KA, Dudley WN. Sleep quality after initial chemotherapy for Breast cancer. Support Care Cancer juin. 2010;18(6):679–89. · DOI
  30. Li W, Kwok CCH, Chan DCW, Ho AWY, Ho CS, Zhang J, et al. Disruption of sleep, sleep-wake activity rhythm, and nocturnal melatonin production in Breast cancer patients undergoing adjuvant chemotherapy: prospective cohort study. Sleep Med mars. 2019;55:14–21. · DOI
  31. Kuo HH, Chiu MJ, Liao WC, Hwang SL. Quality of Sleep and related factors during chemotherapy in patients with stage I/II Breast Cancer. J Formos Med Assoc. 2006;105(1):64–9. · DOI
  32. Ancoli-Israel S, Liu L, Marler MR, Parker BA, Jones V, Sadler GR, Dimsdale J, Cohen-Zion M, Fiorentino L. Fatigue, sleep, and circadian rhythms prior to chemotherapy for Breast cancer. Supportive care in cancer: Official Journal of the Multinational Association of Supportive Care in Cancer. 2006;14(3):201–9. https://doi.org/10.1007/s00520-005-0861-0. · DOI
  33. Berger AM, Farr LA, Kuhn BR, Fischer P, Agrawal S. Values of Sleep/Wake, Activity/Rest, circadian rhythms, and fatigue prior to adjuvant Breast Cancer Chemotherapy. J Pain Symptom Manag. 2007;33(4):398–409. https://doi.org/10.1016/j.jpainsymman.2006.09.022. · DOI
  34. Roscoe JA, Perlis ML, Pigeon WR, O’Neill KH, Heckler CE, Matteson-Rusby SE, et al. Few changes observed in Polysomnographic-assessed sleep before and after completion of Chemotherapy. J Psychosom Res déc. 2011;71(6):423–8. · DOI
  35. Silberfarb PM, Hauri PJ, Oxman TE, Schnurr P. Assessment of sleep in patients with Lung cancer and Breast cancer. J Clin Oncology: Official J Am Soc Clin Oncol. 1993;11(5):997–1004. https://doi.org/10.1200/JCO.1993.11.5.997. · DOI
  36. Eldin ET, Younis SG, Aziz L, Eldin AT, Erfan ST. Evaluation of sleep pattern disorders in Breast cancer patients receiving adjuvant treatment (chemotherapy and/or radiotherapy) using polysomnography. J BUON. 2019;24(2):529–34.
  37. Parker KP, Bliwise DL, Ribeiro M, Jain SR, Vena CI, Kohles-Baker MK, et al. Sleep/Wake patterns of individuals with Advanced Cancer measured by Ambulatory Polysomnography. J Clin Oncol 20 mai. 2008;26(15):2464–72. · DOI
  38. Scullin MK, Bliwise DL. Sleep, cognition, and normal aging: integrating a half century of Multidisciplinary Research. Perspect Psychol Sci Janv. 2015;10(1):97–137. · DOI
  39. Born J. Slow-wave sleep and the consolidation of long-term memory. World J Biol Psychiatry janv. 2010;11(sup1):16–21. · DOI
  40. Bryant NB, Nadel L, Gómez RL. Associations between sleep and episodic memory updating. Hippocampus août. 2020;30(8):794–805. · DOI
  41. Mander BA, Winer JR, Walker MP. Sleep and Human Aging Neuron 5 avr. 2017;94(1):19–36.
  42. Duivon M, Perrier J, Segura-Djezzar C, Joly F, Rehel S, Berthomier C, et al. Sleep-dependent memory consolidation in Breast cancer: use of a virtual reality prospective memory task. Front Neurosci 7 sept. 2022;16:908268. · DOI
  43. Abraham J, Haut MW, Moran MT, Filburn S, Lemiuex S, Kuwabara H. Adjuvant chemotherapy for Breast Cancer: effects on Cerebral White Matter seen in Diffusion Tensor Imaging. Clin Breast Cancer févr. 2008;8(1):88–91. · DOI
  44. Deprez S, Amant F, Smeets A, Peeters R, Leemans A, Van Hecke W, et al. Longitudinal Assessment of Chemotherapy-Induced Structural changes in Cerebral White Matter and its correlation with impaired cognitive functioning. J Clin Oncol 20 janv. 2012;30(3):274–81. · DOI
  45. Tong T, Lu H, Zong J, Lv Q, Chu X. Chemotherapy-related cognitive impairment in patients with Breast cancer based on MRS and DTI analysis. Breast Cancer sept. 2020;27(5):893–902. · DOI
  46. de Ruiter MB, Reneman L, Boogerd W, Veltman DJ, Caan M, Douaud G, et al. Late effects of high-dose adjuvant chemotherapy on white and gray matter in Breast cancer survivors: converging results from multimodal magnetic resonance imaging. Hum Brain Mapp déc. 2012;33(12):2971–83. · DOI
  47. Inagaki M, Yoshikawa E, Matsuoka Y, Sugawara Y, Nakano T, Akechi T, et al. Smaller regional volumes of brain gray and white matter demonstrated in Breast cancer survivors exposed to adjuvant chemotherapy. Cancer 1 janv. 2007;109(1):146–56. · DOI
  48. Koppelmans V, de Ruiter MB, van der Lijn F, Boogerd W, Seynaeve C, van der Lugt A, et al. Global and focal brain volume in long-term Breast cancer survivors exposed to adjuvant chemotherapy. Breast Cancer Res Treat 1 avr. 2012;132(3):1099–106. · DOI
  49. Lange M, Joly F, Vardy J, Ahles T, Dubois M, Tron L, et al. Cancer-related cognitive impairment: an update on state of the art, detection, and management strategies in cancer survivors. Ann Oncol déc. 2019;30(12):1925–40. · DOI · Paper page
  50. Lepage C, Smith AM, Moreau J, Barlow-Krelina E, Wallis N, Collins B, et al. A prospective study of grey matter and cognitive function alterations in chemotherapy-treated Breast cancer patients. SpringerPlus 19 août. 2014;3:444. · DOI
  51. Morin CM, Belleville G, Bélanger L, Ivers H. The Insomnia Severity Index: psychometric indicators to detect insomnia cases and evaluate treatment response. Sleep 1 mai. 2011;34(5):601–8. · DOI · Paper page
  52. Netzer NC, Stoohs RA, Netzer CM, Clark K, Strohl KP. Using the Berlin Questionnaire to identify patients at risk for the Sleep Apnea Syndrome. Ann Intern Med. oct 1999;5(7):485. · DOI · Paper page
  53. Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research. Psychiatry Res mai. 1989;28(2):193–213. · DOI · Paper page
  54. Horne JA, Östberg O. A self-assessment questionnaire to determine morningness-eveningness in human circadian rhythms. Int J Chronobiol. 1976. · DOI
  55. Martinez-Nicolas A, Martinez-Madrid MJ, Almaida-Pagan PF, Bonmati-Carrion MA, Madrid JA, Rol MA. Assessing chronotypes by ambulatory circadian monitoring. Front Physiol. nov 2019;20:10:1396. · DOI
  56. Joly F, Lange M, Rigal O, Correia H, Giffard B, Beaumont JL, et al. French version of the Functional Assessment of Cancer therapy–cognitive function (FACT-Cog) version 3. Support Care Cancer déc. 2012;20(12):3297–305. · DOI
  57. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol mars. 1993;11(3):570–9. · DOI · Paper page
  58. Cleeland CS, Ryan K. The brief pain inventory. Pain Res Group. 1991;20:143–7.
  59. Webster K, Cella D, Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation. Health Qual Life Outcomes. 16 déc 2003;1:79. · DOI
  60. Smets EMA, Garssen B, Bonke B, De Haes JCJM. The multidimensional fatigue inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res avr. 1995;39(3):315–25. · DOI
  61. Beck AT. An inventory for Measuring Depression. Arch Gen Psychiatry 1 juin. 1961;4(6):561. · DOI · Paper page
  62. Galasso L, Montaruli A, Mulè A, Castelli L, Bruno E, Pasanisi P, et al. Rest-activity rhythm in Breast cancer survivors: an update based on non-parametric indices. Chronobiol Int 2 juin. 2020;37(6):946–51. · DOI
  63. Martin T, Duivon M, Bessot N, Grellard JM, Emile G, Polvent S, et al. Rest activity rhythms characteristics of Breast cancer women following endocrine therapy. Sleep 11 avr. 2022;45(4):zsab248. · DOI
  64. Bernard P, Savard J, Steindorf K, Sweegers MG, Courneya KS, Newton RU, et al. Effects and moderators of exercise on sleep in adults with cancer: individual patient data and aggregated meta-analyses. J Psychosom Res 1 sept. 2019;124:109746. · DOI
  65. Kreutz C, Schmidt ME, Steindorf K. Effects of physical and mind–body exercise on sleep problems during and after Breast cancer treatment: a systematic review and meta-analysis. Breast Cancer Res Treat Juill. 2019;176(1):1–15. · DOI
  66. Mölle M, Marshall L, Gais S, Born J. Grouping of spindle activity during slow oscillations in human Non-rapid Eye Movement Sleep. J Neurosci 15 déc. 2002;22(24):10941–7. · DOI · Paper page
  67. Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: a brief Screening Tool for mild cognitive impairment: MOCA: a BRIEF SCREENING TOOL FOR MCI. J Am Geriatr Soc avr. 2005;53(4):695–9. · DOI · Paper page
  68. Rieu D, Bachoud-Lévi AC, Laurent A, Jurion E, Dalla Barba G. Adaptation française Du « Hopkins verbal learning test ». Rev Neurol (Paris) juin. 2006;162(6–7):721–8. · DOI
  69. Stroop JR. Studies of interference in serial verbal reactions. J Exp Psychol. 1935;18(6):643. · DOI · Paper page
  70. Cardebat D, Doyon B, Puel M, Goulet P, Joanette Y. Evocation lexicale Formelle et sémantique chez des sujets normaux. Performances et dynamiques de production en fonction du sexe, de l’âge et du niveau d’étude. Acta Neurol Belg. 1990;90(4):207–17.
  71. Gauthier K, Morand A, Dutheil F, Alescio-Lautier B, Boucraut J, Clarys D, et al. Ageing stereotypes and prodromal Alzheimer’s Disease (AGING): study protocol for an ongoing randomised clinical study. BMJ Open. oct 2019;7(10):e032265. · DOI
  72. Hilliard D, Passow S, Thurm F, Schuck NW, Garthe A, Kempermann G, et al. Noisy galvanic vestibular stimulation modulates spatial memory in young healthy adults. Sci Rep 27 juin. 2019;9(1):9310. · DOI
  73. Lange M, Clarisse B, Leconte A, Dembélé KP, Lequesne J, Nicola C, et al. Cognitive assessment in patients treated by immunotherapy: the prospective Cog-Immuno trial. BMC Cancer 13 déc. 2022;22:1308. · DOI
  74. Caplette-Gingras A, Savard J, Savard MH, Ivers H. Is Insomnia Associated with cognitive impairments in Breast Cancer patients? Behav Sleep Med sept. 2013;11(4):239–57. · DOI
  75. Liou KT, Ahles TA, Garland SN, Li QS, Bao T, Li Y, et al. The relationship between Insomnia and cognitive impairment in Breast Cancer survivors. JNCI Cancer Spectr 7 juin. 2019;3(3):pkz041. · DOI · Paper page
  76. Xu S, Thompson W, Ancoli-Israel S, Liu L, Palmer B, Natarajan L. Cognition, quality-of-life, and symptom clusters in Breast cancer: using bayesian networks to elucidate complex relationships. Psychooncology mars. 2018;27(3):802–9. · DOI
  77. Fleming L, Randell K, Stewart E, Espie CA, Morrison DS, Lawless C et al. Insomnia in Breast cancer: a prospective observational study. Sleep [Internet]. 1 mars 2019 [cité 24 Nov 2022];42(3). Disponible sur: https://academic.oup.com/sleep/article/doi/https://doi.org/10.1093/sleep/zsy245/5231798. · DOI
  78. Perrier J, Duivon M, Clochon P, Rehel S, Doidy F, Grellard JM, et al. Sleep macro- and microstructure in Breast cancer survivors. Sci Rep 15 févr. 2022;12(1):2557. · DOI
  79. Schmidt ME, Chang-Claude J, Vrieling A, Heinz J, Flesch-Janys D, Steindorf K. Fatigue and quality of life in Breast cancer survivors: temporal courses and long-term pattern. J Cancer Surviv mars. 2012;6(1):11–9. · DOI
  80. Palesh O, Peppone, Innominato J, Jeong M, Sprod L et al. Prevalence, putative mechanisms, and current management of sleep problems during chemotherapy for cancer. Nat Sci Sleep déc 2012;151. · DOI
  81. Sousa H, Almeida S, Bessa J, Pereira MG. The Developmental Trajectory of Cancer-related cognitive impairment in Breast Cancer patients: a systematic review of Longitudinal Neuroimaging studies. Neuropsychol Rev 1 sept. 2020;30(3):287–309. · DOI
  82. Vien C, Boré A, Boutin A, Pinsard B, Carrier J, Doyon J, et al. Thalamo-cortical White Matter underlies motor memory consolidation via modulation of Sleep spindles in Young and older adults. Neurosci 15 mars. 2019;402:104–15. · DOI
  83. Piantoni G, Poil SS, Linkenkaer-Hansen K, Verweij IM, Ramautar JR, Van Someren EJW, et al. Individual Differences in White Matter Diffusion affect sleep oscillations. J Neurosci 2 janv. 2013;33(1):227–33. · DOI

Metadata

Authors
Elia, C., de Girolamo, L., Clarisse, B., Galin, M., Rehel, S., Clochon, P., Doidy, F., Segobin, S., Viader, F., Naveau, M., Delcroix, N., Segura-Djezzar, C., Grellard, J.-M., Lequesne, J., Etard, O., Martin, T., Quarck, G., Eustache, F., Joly, F., Giffard, B., & Perrier, J.
Venue
BMC Cancer
Publisher
Springer Science and Business Media LLC
Published
2023-12-01
Volume
23
Issue
1
ISSN
1471-2407
DOI
10.1186/s12885-023-11664-x
Cited by
6
References
4
Language
en
Licence
Funders
  • Université de Caen Normandie (Doctoral Contract)
  • Région Normandie (Chair of excellence 2020)
  • Fondation ARC pour la Recherche sur le Cancer (ARCPJA2021060003783)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.